Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes
Douglas MacDonald(University of Detroit Mercy), Nicholas Papadopoulos(Regeneron (United States))
Cited by 44
Related Papers
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
|Proceedings of the National Academy of Sciences|2007|203